Avidity Biosciences Inc. Unveils Presentation on Advancements in RNA Therapeutics and AOC Platform for Neuromuscular Diseases

Reuters

06-10

Avidity Biosciences Inc. Unveils Presentation on Advancements in RNA <a href="https://laohu8.com/S/LENZ">Therapeutics</a> and AOC Platform for Neuromuscular Diseases

Avidity Biosciences Inc. recently presented its corporate update, focusing on its proprietary Antibody Oligonucleotide Conjugate (AOC) platform, which aims to revolutionize RNA therapeutics delivery. The platform's advantages include targeting new tissue and cell types beyond the liver and maximizing therapeutic durability for infrequent dosing. The company highlighted its progress in advancing three potentially registrational clinical trials and expanding the AOC platform to precision cardiology and next-generation technology innovations. Avidity Biosciences also emphasized its strong cash position of approximately $1.4 billion, providing funding into mid-2027. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avidity Biosciences Inc. published the original content used to generate this news brief on June 09, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2542120353"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2542120353\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2542120353?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-10 06:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2542120353","market":"nz","top_or_hot":-1,"title":"Avidity Biosciences Inc. Unveils Presentation on Advancements in RNA Therapeutics and AOC Platform for Neuromuscular Diseases","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Avidity Biosciences Inc. Unveils Presentation on Advancements in RNA <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> and AOC Platform for Neuromuscular Diseases\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Avidity Biosciences Inc. recently presented its corporate update, focusing on its proprietary Antibody Oligonucleotide Conjugate (AOC) platform, which aims to revolutionize RNA therapeutics delivery. The platform's advantages include targeting new tissue and cell types beyond the liver and maximizing therapeutic durability for infrequent dosing. The company highlighted its progress in advancing three potentially registrational clinical trials and expanding the AOC platform to precision cardiology and next-generation technology innovations. Avidity Biosciences also emphasized its strong cash position of approximately $1.4 billion, providing funding into mid-2027. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avidity Biosciences Inc. published the original content used to generate this news brief on June 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Avidity Biosciences Inc. Unveils Presentation on Advancements in RNA Therapeutics and AOC Platform for Neuromuscular Diseases</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAvidity Biosciences Inc. Unveils Presentation on Advancements in RNA Therapeutics and AOC Platform for Neuromuscular Diseases\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-10 06:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Avidity Biosciences Inc. Unveils Presentation on Advancements in RNA <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> and AOC Platform for Neuromuscular Diseases\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Avidity Biosciences Inc. recently presented its corporate update, focusing on its proprietary Antibody Oligonucleotide Conjugate (AOC) platform, which aims to revolutionize RNA therapeutics delivery. The platform's advantages include targeting new tissue and cell types beyond the liver and maximizing therapeutic durability for infrequent dosing. The company highlighted its progress in advancing three potentially registrational clinical trials and expanding the AOC platform to precision cardiology and next-generation technology innovations. Avidity Biosciences also emphasized its strong cash position of approximately $1.4 billion, providing funding into mid-2027. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avidity Biosciences Inc. published the original content used to generate this news brief on June 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250609:nNDL3dhQjs:1","article_id":"2542120353","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2542120353","pubTimestamp":1749508495,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Avidity Biosciences Inc. Unveils Presentation on Advancements in RNA Therapeutics and AOC Platform for Neuromuscular Diseases. Avidity Biosciences Inc. recently presented its corporate update, focusing on its proprietary Antibody Oligonucleotide Conjugate  platform, which aims to revolutionize RNA therapeutics delivery. The platform's advantages include targeting new tissue and cell types beyond the liver and maximizing therapeutic durability for infrequent dosing. The company highlighted its progress in advancing three potentially registrational clinical trials and expanding the AOC platform to precision cardiology and next-generation technology innovations. Avidity Biosciences also emphasized its strong cash position of approximately $1.4 billion, providing funding into mid-2027. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate an","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Avidity Biosciences Inc.推出神经肌肉疾病RNA疗法和AOC平台进展演示","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RNA":0.9},"content_text":"Avidity Biosciences Inc. Unveils Presentation on Advancements in RNA Therapeutics and AOC Platform for Neuromuscular Diseases\n    \n\n        Avidity Biosciences Inc. recently presented its corporate update, focusing on its proprietary Antibody Oligonucleotide Conjugate (AOC) platform, which aims to revolutionize RNA therapeutics delivery. The platform's advantages include targeting new tissue and cell types beyond the liver and maximizing therapeutic durability for infrequent dosing. The company highlighted its progress in advancing three potentially registrational clinical trials and expanding the AOC platform to precision cardiology and next-generation technology innovations. Avidity Biosciences also emphasized its strong cash position of approximately $1.4 billion, providing funding into mid-2027. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avidity Biosciences Inc. published the original content used to generate this news brief on June 09, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}